CureVac N.V (CVAC) News
Filter CVAC News Items
CVAC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVAC News Highlights
- CVAC's 30 day story count now stands at 2.
- Over the past 5 days, the trend for CVAC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CVAC News From Around the Web
Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.
CureVac Announces Voting Results of Extraordinary General Meeting/ CureVac N.V. |
As CureVac N.V.'s market cap (NASDAQ:CVAC) drops to US$1.4b, insiders might be questioning their decision to buy earlier this yearThe recent 7.1% drop in CureVac N.V.'s ( NASDAQ:CVAC ) stock could come as a blow to insiders who purchased €97m worth... |
The past year for CureVac (NASDAQ:CVAC) investors has not been profitableWhile it may not be enough for some shareholders, we think it is good to see the CureVac N.V. ( NASDAQ:CVAC ) share... |
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares/ CureVac N.V. |
CureVac Announces Proposed Public Offering of Common SharesCureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of its common shares in an underwritten public offering. |
CureVac Welcomes Myriam Mendila as New Chief Development Officer/ CureVac N.V. |
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)/ CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its inclusion in the second annual "Innovation Momentum: Global Top 100" report by LexisNexis®. Top 100 recognizes companies advancing innovative solutions to address today's challenges and laying the intellectual property foundations for further breakthroughs. |
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine ProgramsCureVac N.V. (NASDAQ: CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK plc (NYSE: GSK). The newly reported data focus on older adult age groups. COVID-19 Program Newly reported immunogenicity data from CV0501 in older adults (age ≥65) are based on the fully recruited dose groups of 12, 25 and 50µg, consisting of 10 subjects per dose. On day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to |
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development ProgramsCureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced positive extended preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu conducted in collaboration with GSK. The newly reported data focus on older adult age groups in both indications. Detailed data can be reviewed in the associated presentation. |
The 3 Best Biotech Stocks Under $1 to Buy for JanuaryEven the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. |